$Moderna, Inc.(MRNA)$ Share pr

$Moderna, Inc.(MRNA)$ Share price could modestly correct from here as the glow of the ESMO presentation dims over time. But it should get a boost again when the New England Journal of Medicine publishes the Intismeran phase 3 adjuvant melanoma trial. A lot of oncologists who read the Journal and pay attention to practice-changing data will be aware of Intismeran by the time it's submitted as a BLA, and then approved by the FDA later next year for marketing. The clear efficacy on top of Keytruda, plus the complete absence of serious side effects, makes Intismeran a unicorn in cancer therapy. Oncologists specializing in melanoma will likely make sure demand stays very strong.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":622770865774672,"tweetId":"622770865774672","gmtCreate":1793045321000,"gmtModify":1793082790397,"author":{"id":10000000000010944,"idStr":"10000000000010944","authorId":10000000000010944,"authorIdStr":"10000000000010944","name":"Antony Kent","avatar":"https://static.tigerbbs.com/c28a3af640493e17a7c4f9669695b49f","vip":8,"userType":8,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"wearingBadges":[],"fanSize":18,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;Share price could modestly correct from here as the glow of the ESMO presentation dims over time. But it should get a boost again when the New England Journal of Medicine publishes the Intismeran phase 3 adjuvant melanoma trial. A lot of oncologists who read the Journal and pay attention to practice-changing data will be aware of Intismeran by the time it's submitted as a BLA, and then approved by the FDA later next year for marketing. The clear efficacy on top of Keytruda, plus the complete absence of serious side effects, makes Intismeran a unicorn in cancer therapy. Oncologists specializing in melanoma will likely make sure demand stays very strong.</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://ttm.financial/S/MRNA\">$Moderna, Inc.(MRNA)$&nbsp;</a><v-v data-views=\"1\"></v-v>&nbsp;Share price could modestly correct from here as the glow of the ESMO presentation dims over time. But it should get a boost again when the New England Journal of Medicine publishes the Intismeran phase 3 adjuvant melanoma trial. A lot of oncologists who read the Journal and pay attention to practice-changing data will be aware of Intismeran by the time it's submitted as a BLA, and then approved by the FDA later next year for marketing. The clear efficacy on top of Keytruda, plus the complete absence of serious side effects, makes Intismeran a unicorn in cancer therapy. Oncologists specializing in melanoma will likely make sure demand stays very strong.</p></body></html>","text":"$Moderna, Inc.(MRNA)$ Share price could modestly correct from here as the glow of the ESMO presentation dims over time. But it should get a boost again when the New England Journal of Medicine publishes the Intismeran phase 3 adjuvant melanoma trial. A lot of oncologists who read the Journal and pay attention to practice-changing data will be aware of Intismeran by the time it's submitted as a BLA, and then approved by the FDA later next year for marketing. The clear efficacy on top of Keytruda, plus the complete absence of serious side effects, makes Intismeran a unicorn in cancer therapy. Oncologists specializing in melanoma will likely make sure demand stays very strong.","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/622770865774672","repostId":0,"isVote":1,"tweetType":1,"viewCount":51,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["MRNA"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":570,"optionInvolvedFlag":false,"subscribersOnly":false,"subscribersOnlyAccessible":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"isCommentEnd":true,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/622770865774672"}